Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Vaccines

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 160 articles:
HTML format
Text format



Single Articles


    September 2019
  1. CHOI KY, El-Hamdi NS, McGregor A
    Inclusion of the viral pentamer complex in a vaccine design greatly improves protection against congenital cytomegalovirus in the guinea pig model.
    J Virol. 2019 Sep 4. pii: JVI.01442-19. doi: 10.1128/JVI.01442.
    PubMed     Text format     Abstract available


    August 2019
  2. JOHNSON J, Freedman H, Logan M, Wong JAJ, et al
    A recombinant HCV genotype 1a E1/E2 envelope glycoprotein vaccine elicits antibodies that differentially neutralize closely related 2a strains through interactions of the N-terminal hypervariable region 1 of E2 with scavenger receptor B1.
    J Virol. 2019 Aug 28. pii: JVI.00810-19. doi: 10.1128/JVI.00810.
    PubMed     Text format     Abstract available


  3. SLIVA K, Martin J, von Rhein C, Herrmann T, et al
    Interference with SAMHD1 restores late gene expression of modified vaccinia virus Ankara (MVA) in human dendritic cells and abrogates type I interferon expression.
    J Virol. 2019 Aug 28. pii: JVI.01097-19. doi: 10.1128/JVI.01097.
    PubMed     Text format     Abstract available


  4. LI SS, Gilbert PB, Carpp LN, Pyo CW, et al
    Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial.
    J Virol. 2019 Aug 21. pii: JVI.02041-18. doi: 10.1128/JVI.02041.
    PubMed     Text format     Abstract available


  5. HENRY C, Palm AE, Utset HA, Huang M, et al
    Monoclonal antibody responses after recombinant HA vaccine versus subunit inactivated influenza virus vaccine: a comparative study.
    J Virol. 2019 Aug 21. pii: JVI.01150-19. doi: 10.1128/JVI.01150.
    PubMed     Text format     Abstract available


  6. ALMOND N, Berry N, Stebbings R, Preston M, et al
    Vaccination of macaques with DNA followed by adenoviral vectors encoding SIV gag alone delays infection by repeated mucosal challenge with SIV.
    J Virol. 2019 Aug 14. pii: JVI.00606-19. doi: 10.1128/JVI.00606.
    PubMed     Text format     Abstract available


  7. DHAKAL S, Klein SL
    Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs.
    J Virol. 2019 Aug 7. pii: JVI.00797-19. doi: 10.1128/JVI.00797.
    PubMed     Text format     Abstract available


  8. WONG YC, Croft S, Smith SA, Lin LCW, et al
    Vaccinia Virus Strain MVA can Induce Optimal CD8(+) T cell responses to Directly Primed Antigens Depending on Vaccine Design.
    J Virol. 2019 Aug 2. pii: JVI.01154-19. doi: 10.1128/JVI.01154.
    PubMed     Text format     Abstract available


  9. HRYCAK CP, Windmann S, Bayer W
    Comparative evaluation of the vaccine efficacy of three adenovirus-based vector types in the Friend retrovirus infection model.
    J Virol. 2019 Aug 2. pii: JVI.01155-19. doi: 10.1128/JVI.01155.
    PubMed     Text format     Abstract available


    July 2019
  10. RICO AB, Wang Z, Olson AT, Linville AC, et al
    The Vaccinia B1 and Cellular VRK2 Kinases Promote Vaccinia Replication Factory Formation through Phosphorylation Dependent Inhibition of Vaccinia B12.
    J Virol. 2019 Jul 24. pii: JVI.00855-19. doi: 10.1128/JVI.00855.
    PubMed     Text format     Abstract available


  11. STYLES TM, Gangadhara S, Reddy PBJ, Hicks S, et al
    HIV C.1086 Envelope Gp140 Protein Boosts Following DNA/MVA Vaccination Fail to Enhance Heterologous Anti-V1V2 Antibody Response and Protection Against Clade C SHIV Challenge.
    J Virol. 2019 Jul 24. pii: JVI.00934-19. doi: 10.1128/JVI.00934.
    PubMed     Text format     Abstract available


  12. RATTAN A, Richards KA, Knowlden ZAG, Sant AJ, et al
    Protein vaccination directs the CD4+ T cell response towards shared protective epitopes that can be recalled after influenza infection.
    J Virol. 2019 Jul 24. pii: JVI.00947-19. doi: 10.1128/JVI.00947.
    PubMed     Text format     Abstract available


  13. NOTARIO L, Redondo-Anton J, Alari-Pahissa E, Albentosa A, et al
    CD69 targeting enhances anti-Vaccinia virus immunity.
    J Virol. 2019 Jul 17. pii: JVI.00553-19. doi: 10.1128/JVI.00553.
    PubMed     Text format     Abstract available


  14. ABDULHAQQ SA, Wu H, Schell JB, Hammond KB, et al
    Vaccine-mediated Inhibition of the Transporter Associated with Antigen Processing is Insufficient to Induce MHC-E Restricted CD8+ T cells in Nonhuman Primates.
    J Virol. 2019 Jul 17. pii: JVI.00592-19. doi: 10.1128/JVI.00592.
    PubMed     Text format     Abstract available


  15. REY LM, Gil JA, Mateus J, Rodriguez LS, et al
    LAP(+) cells modulate protection induced by oral vaccination with Rhesus Rotavirus in a neonatal mouse model.
    J Virol. 2019 Jul 10. pii: JVI.00882-19. doi: 10.1128/JVI.00882.
    PubMed     Text format     Abstract available


  16. MEKONNEN ZA, Grubor-Bauk B, English K, Leung P, et al
    Single dose vaccination with a hepatotropic Adeno-associated virus (AAV) efficiently localises T cell immunity in the liver with the potential to confer rapid protection against hepatitis C virus (HCV).
    J Virol. 2019 Jul 10. pii: JVI.00202-19. doi: 10.1128/JVI.00202.
    PubMed     Text format     Abstract available


  17. SHEPHERD N, Lan J, Li W, Rane S, et al
    Primary human B cells at different differentiation and maturation stages exhibit distinct susceptibilities to vaccinia virus binding and infection.
    J Virol. 2019 Jul 10. pii: JVI.00973-19. doi: 10.1128/JVI.00973.
    PubMed     Text format     Abstract available


  18. LI X, Gao Y, Ye Z
    A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.
    J Virol. 2019 Jul 3. pii: JVI.00570-19. doi: 10.1128/JVI.00570.
    PubMed     Text format     Abstract available


  19. CARRAU L, Rezelj VV, Noval MG, Levi LI, et al
    Chikungunya virus vaccine candidates with decreased mutational robustness are attenuated in vivo and have compromised transmissibility.
    J Virol. 2019 Jul 3. pii: JVI.00775-19. doi: 10.1128/JVI.00775.
    PubMed     Text format     Abstract available


    June 2019
  20. ALFAJARO MM, Kim JY, Barbe L, Cho EH, et al
    Dual Recognition of Sialic Acid and alphaGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains.
    J Virol. 2019 Jun 26. pii: JVI.00941-19. doi: 10.1128/JVI.00941.
    PubMed     Text format     Abstract available


  21. PASIN C, Balelli I, Van Effelterre T, Bockstal V, et al
    Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation.
    J Virol. 2019 Jun 26. pii: JVI.00579-19. doi: 10.1128/JVI.00579.
    PubMed     Text format     Abstract available


  22. ROY S, Coulon PG, Prakash S, Srivastava R, et al
    Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restore the Function of Anti-Viral Tissue-Resident CD8(+) TRM Cells and Reduce Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits.
    J Virol. 2019 Jun 19. pii: JVI.00827-19. doi: 10.1128/JVI.00827.
    PubMed     Text format     Abstract available


  23. TAI W, Chen J, Zhao G, Geng Q, et al
    Rational design of Zika virus subunit vaccine with enhanced efficacy.
    J Virol. 2019 Jun 12. pii: JVI.02187-18. doi: 10.1128/JVI.02187.
    PubMed     Text format     Abstract available


  24. LI N, Zhang YN, Deng CL, Shi PY, et al
    Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus.
    J Virol. 2019 Jun 12. pii: JVI.00720-19. doi: 10.1128/JVI.00720.
    PubMed     Text format     Abstract available


  25. ZOLLA-PAZNER S, Gilbert PB
    REVISITING THE CORRELATE OF REDUCED HIV INFECTION RISK IN THE RV144 VACCINE TRIAL.
    J Virol. 2019 Jun 12. pii: JVI.00629-19. doi: 10.1128/JVI.00629.
    PubMed     Text format     Abstract available


    May 2019
  26. HOU Y, Ke H, Kim J, Yoo D, et al
    Engineering a live attenuated PEDV vaccine candidate via inactivation of the viral 2'-O methyltransferase and the endocytosis signal of the spike protein.
    J Virol. 2019 May 22. pii: JVI.00406-19. doi: 10.1128/JVI.00406.
    PubMed     Text format     Abstract available


  27. MEADE N, King M, Munger J, Walsh D, et al
    mTOR dysregulation by vaccinia virus F17 controls multiple processes with varying roles in infection.
    J Virol. 2019 May 22. pii: JVI.00784-19. doi: 10.1128/JVI.00784.
    PubMed     Text format     Abstract available


  28. WEINBERG A, Pang L, Johnson MJ, Caldas Y, et al
    The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and VZV-Specific T Cell Immunity.
    J Virol. 2019 May 15. pii: JVI.00305-19. doi: 10.1128/JVI.00305.
    PubMed     Text format     Abstract available


  29. ZHANG YN, Deng CL, Li JQ, Li N, et al
    Infectious Chikungunya Virus with a Complete Capsid Deletion: a New Approach for CHIKV Vaccine.
    J Virol. 2019 May 15. pii: JVI.00504-19. doi: 10.1128/JVI.00504.
    PubMed     Text format     Abstract available


  30. JONES DI, Pollara JJ, Johnson-Weaver BT, LaBranche CC, et al
    Optimized Mucosal MVA Prime/Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen.
    J Virol. 2019 May 8. pii: JVI.00475-19. doi: 10.1128/JVI.00475.
    PubMed     Text format     Abstract available


    April 2019
  31. GOFFIN E, Javaux J, Destexhe E, Pretto CD, et al
    Oral vaccination with replication-competent adenovirus in mice reveals the dissemination of the viral vaccine beyond the gastrointestinal tract.
    J Virol. 2019 Apr 17. pii: JVI.00237-19. doi: 10.1128/JVI.00237.
    PubMed     Text format     Abstract available


  32. PANT A, Cao S, Yang Z
    Asparagine is a critical limiting metabolite for vaccinia virus protein synthesis during glutamine deprivation.
    J Virol. 2019 Apr 17. pii: JVI.01834-18. doi: 10.1128/JVI.01834.
    PubMed     Text format     Abstract available


  33. CALATAYUD O, Esperon F, Cleaveland S, Biek R, et al
    Carnivore parvovirus ecology in the Serengeti ecosystem: vaccine strains circulating and new host species identified.
    J Virol. 2019 Apr 17. pii: JVI.02220-18. doi: 10.1128/JVI.02220.
    PubMed     Text format     Abstract available


  34. LUTEIJN RD, van Diemen F, Blomen VA, Boer IGJ, et al
    A genome-wide haploid genetic screen identifies heparan sulfate-associated genes and the macropinocytosis modulator TMED10 as factors supporting vaccinia virus infection.
    J Virol. 2019 Apr 17. pii: JVI.02160-18. doi: 10.1128/JVI.02160.
    PubMed     Text format     Abstract available


  35. TSAI YH, Huang SW, Hsieh WS, Cheng CK, et al
    Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next Generation Vaccine Candidate.
    J Virol. 2019 Apr 17. pii: JVI.02308-18. doi: 10.1128/JVI.02308.
    PubMed     Text format     Abstract available


  36. SUN W, Kirkpatrick E, Ermler M, Nachbagauer R, et al
    Development of Influenza B Universal Vaccine Candidates using the "Mosaic" Hemagglutinin Approach.
    J Virol. 2019 Apr 3. pii: JVI.00333-19. doi: 10.1128/JVI.00333.
    PubMed     Text format     Abstract available


    March 2019
  37. KLEINPETER P, Remy-Ziller C, Winter E, Gantzer M, et al
    By binding CD80 and CD86, the vaccinia virus' M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80's binding to PD-L1.
    J Virol. 2019 Mar 27. pii: JVI.00207-19. doi: 10.1128/JVI.00207.
    PubMed     Text format     Abstract available


  38. POLLARA J, Jones DI, Huffman T, Edwards RW, et al
    Bridging vaccine-induced HIV-1 neutralizing and effector antibody responses in rabbit and rhesus macaque animal models.
    J Virol. 2019 Mar 6. pii: JVI.02119-18. doi: 10.1128/JVI.02119.
    PubMed     Text format     Abstract available


    February 2019
  39. PALLETT MA, Ren H, Zhang RY, Scutts SR, et al
    Vaccinia virus BBK E3 ligase adaptor A55 targets importin-dependent NF-kappaB activation and inhibits CD8(+) T-cell memory.
    J Virol. 2019 Feb 27. pii: JVI.00051-19. doi: 10.1128/JVI.00051.
    PubMed     Text format     Abstract available


  40. SRIVASTAVA R, Roy S, Coulon PA, Vahed H, et al
    Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4(+) and CD8(+) TRM Cells Associated with Protection Against Recurrent Genit
    J Virol. 2019 Feb 20. pii: JVI.02309-18. doi: 10.1128/JVI.02309.
    PubMed     Text format     Abstract available


  41. VAN DIEPEN MT, Chapman R, Douglass N, Galant S, et al
    Prime boost immunisations with DNA, MVA and protein-based vaccines elicit robust HIV-1, Tier 2 neutralizing antibodies against the CAP256 superinfecting virus.
    J Virol. 2019 Feb 13. pii: JVI.02155-18. doi: 10.1128/JVI.02155.
    PubMed     Text format     Abstract available


  42. WU Q, Rivailler P, Xu S, Xu W, et al
    Comparison of the whole genome sequence of an Oka varicella vaccine from China with other Oka vaccine strains reveals sites putatively critical for vaccine efficacy.
    J Virol. 2019 Feb 6. pii: JVI.02281-18. doi: 10.1128/JVI.02281.
    PubMed     Text format     Abstract available


    January 2019
  43. ZOU C, Murakoshi H, Kuse N, Akahoshi T, et al
    Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
    J Virol. 2019 Jan 23. pii: JVI.02142-18. doi: 10.1128/JVI.02142.
    PubMed     Text format     Abstract available


  44. MARIN MQ, Perez P, Ljungberg K, Sorzano COS, et al
    Potent Anti-Hepatitis C (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-launched RNA Replicons and MVA-HCV.
    J Virol. 2019 Jan 23. pii: JVI.00055-19. doi: 10.1128/JVI.00055.
    PubMed     Text format     Abstract available


  45. BURTON S, Spicer LM, Charles TP, Gangadhara S, et al
    Clade C HIV-1 envelope vaccination regimens differ in their ability to elicit antibodies with moderate neutralization breadth against genetically diverse tier 2 HIV-1 envelope variants.
    J Virol. 2019 Jan 16. pii: JVI.01846-18. doi: 10.1128/JVI.01846.
    PubMed     Text format     Abstract available


    December 2018
  46. DE FREITAS LFD, Oliveira RP, Miranda MCG, Rocha RP, et al
    The virulence of different Vaccinia virus strains is directly proportional to their ability in down modulating specific cell-mediated immune compartments in vivo.
    J Virol. 2018 Dec 19. pii: JVI.02191-18. doi: 10.1128/JVI.02191.
    PubMed     Text format     Abstract available


  47. MOSHKANI S, Chiale C, Lang SM, Rose JK, et al
    A highly attenuated vesicular stomatitis virus-based vaccine platform controls HBV replication in mouse models of hepatitis B.
    J Virol. 2018 Dec 12. pii: JVI.01586-18. doi: 10.1128/JVI.01586.
    PubMed     Text format     Abstract available


  48. MARTINS MA, Gonzalez-Nieto L, Shin YC, Domingues A, et al
    Vaccine-induced T-cell responses do not predict the rate of acquisition after repeated intrarectal SIVmac239 challenges in Mamu-B*08+ rhesus macaques.
    J Virol. 2018 Dec 12. pii: JVI.01626-18. doi: 10.1128/JVI.01626.
    PubMed     Text format     Abstract available


  49. DENNIS M, Eudailey J, Pollara J, McMillan AS, et al
    Co-administration of CH31 broadly neutralizing antibody does not affect development of vaccine-induced anti-HIV-1 envelope antibody responses in infant Rhesus macaques.
    J Virol. 2018 Dec 12. pii: JVI.01783-18. doi: 10.1128/JVI.01783.
    PubMed     Text format     Abstract available


  50. KIMBLE JB, Malherbe DC, Meyer M, Gunn BM, et al
    ANTIBODY-MEDIATED PROTECTIVE MECHANISMS INDUCED BY A TRIVALENT PARAINFLUENZA-VECTORED EBOLAVIRUS VACCINE.
    J Virol. 2018 Dec 5. pii: JVI.01845-18. doi: 10.1128/JVI.01845.
    PubMed     Text format     Abstract available


  51. NELSON CS, Cruz DV, Su M, Xie G, et al
    Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees.
    J Virol. 2018 Dec 5. pii: JVI.01695-18. doi: 10.1128/JVI.01695.
    PubMed     Text format     Abstract available


    November 2018
  52. MONTICELLI SR, Earley AK, Tate J, Ward BM, et al
    The Ectodomain of the Vaccinia Virus Glycoprotein A34 is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with the Glycoprotein B5.
    J Virol. 2018 Nov 21. pii: JVI.01343-18. doi: 10.1128/JVI.01343.
    PubMed     Text format     Abstract available


  53. ASBACH B, Kibler KV, Kostler J, Perdiguero B, et al
    Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost.
    J Virol. 2018 Nov 14. pii: JVI.01529-18. doi: 10.1128/JVI.01529.
    PubMed     Text format     Abstract available


  54. NURNBERGER C, Bodmer BS, Fiedler AH, Gabriel G, et al
    A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy model.
    J Virol. 2018 Nov 14. pii: JVI.01485-18. doi: 10.1128/JVI.01485.
    PubMed     Text format     Abstract available


    October 2018
  55. HUSSAIN S, Turnbull ML, Wise HM, Jagger BW, et al
    Mutation of influenza A virus PA-X decreases pathogenicity in chicken embryos and can increase the yield of reassortant candidate vaccine viruses.
    J Virol. 2018 Oct 31. pii: JVI.01551-18. doi: 10.1128/JVI.01551.
    PubMed     Text format     Abstract available


  56. AN Y, Parsons LM, Jankowska E, Melnyk D, et al
    N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for potency testing and immune processing.
    J Virol. 2018 Oct 24. pii: JVI.01693-18. doi: 10.1128/JVI.01693.
    PubMed     Text format     Abstract available


  57. OGDEN KM, Tan Y, Akopov A, Stewart LS, et al
    Multiple introductions and antigenic mismatch with vaccines may contribute to increased predominance of G12P[8] rotaviruses in the United States.
    J Virol. 2018 Oct 17. pii: JVI.01476-18. doi: 10.1128/JVI.01476.
    PubMed     Text format     Abstract available


    September 2018
  58. HODGSON S, Moffat K, Hill H, Flannery JT, et al
    Comparison of the immunogenicity and cross-lineage efficacy of live attenuated peste des petits ruminants virus vaccines PPRV/Nigeria/75/1 and PPRV/Sungri/96.
    J Virol. 2018 Sep 26. pii: JVI.01471-18. doi: 10.1128/JVI.01471.
    PubMed     Text format     Abstract available


  59. FREI JC, Wirchnianski AS, Govero J, Vergnolle O, et al
    Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  60. SIVAN G, Glushakow-Smith SG, Katsafanas GC, Americo JL, et al
    Human host-range restriction of the vaccinia virus C7/K1 double deletion mutant is mediated by an atypical mode of translation inhibition.
    J Virol. 2018 Sep 12. pii: JVI.01329-18. doi: 10.1128/JVI.01329.
    PubMed     Text format     Abstract available


  61. PISSANI F, Schulte B, Eller MA, Schultz BT, et al
    Modulation of Vaccine-induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    J Virol. 2018 Sep 12. pii: JVI.01143-18. doi: 10.1128/JVI.01143.
    PubMed     Text format     Abstract available


  62. TSAI WY, Chen HL, Tsai JJ, Dejnirattisai W, et al
    Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine.
    J Virol. 2018 Sep 5. pii: JVI.00556-18. doi: 10.1128/JVI.00556.
    PubMed     Text format     Abstract available


  63. DARRICARRERE N, Pougatcheva S, Duan X, Rudicell RS, et al
    Development of a Pan-H1 Influenza Vaccine.
    J Virol. 2018 Sep 5. pii: JVI.01349-18. doi: 10.1128/JVI.01349.
    PubMed     Text format     Abstract available


  64. ABENTE EJ, Rajao DS, Santos J, Kaplan BS, et al
    Comparison of adjuvanted-whole inactivated virus and live-attenuated virus vaccines against challenge with contemporary, antigenically distinct swine H3N2 influenza A viruses.
    J Virol. 2018 Sep 5. pii: JVI.01323-18. doi: 10.1128/JVI.01323.
    PubMed     Text format     Abstract available


  65. DAVIDO DJ, Tu EM, Wang H, Korom M, et al
    Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  66. BROCK LG, Liu X, Liang B, Lingemann M, et al
    Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


    August 2018
  67. WAN Z, Cardenas Garcia S, Liu J, Santos J, et al
    An alternative strategy as a quadrivalent live attenuated influenza virus vaccine.
    J Virol. 2018 Aug 22. pii: JVI.01025-18. doi: 10.1128/JVI.01025.
    PubMed     Text format     Abstract available


  68. SHAN C, Xie X, Zou J, Zust R, et al
    Using a virion assembly-defective dengue virus as a vaccine approach.
    J Virol. 2018 Aug 15. pii: JVI.01002-18. doi: 10.1128/JVI.01002.
    PubMed     Text format     Abstract available


  69. BLOOM DC, Tran RK, Feller J, Voellmy R, et al
    Immunization by Replication-Competent Controlled Herpesvirus Vectors.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  70. MARIN-LOPEZ A, Calvo-Pinilla E, Barriales D, Lorenzo G, et al
    CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR(-/-) Mice.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  71. PHILLIPS B, Van Rompay KKA, Rodriguez-Nieves J, Lorin C, et al
    Adjuvant-dependent enhancement of HIV Env-specific antibody responses in infant rhesus macaques.
    J Virol. 2018 Aug 8. pii: JVI.01051-18. doi: 10.1128/JVI.01051.
    PubMed     Text format     Abstract available


  72. PERMAR SR, Schleiss MR, Plotkin SA
    Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection".
    J Virol. 2018;92.
    PubMed     Text format    


  73. GANTT S, Marchant A, Boppana SB
    Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection.
    J Virol. 2018;92.
    PubMed     Text format    


  74. KIENER R, Fleischmann M, Wiegand MA, Lemmermann NAW, et al
    Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  75. KIM YJ, Kim KH, Ko EJ, Kim MC, et al
    Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain Specific HA or Cross Protective M2e vaccination.
    J Virol. 2018 Aug 1. pii: JVI.00969-18. doi: 10.1128/JVI.00969.
    PubMed     Text format     Abstract available


    July 2018
  76. STUART CA, Zhivkoplias EK, Senkevich TG, Wyatt LS, et al
    RNA polymerase mutations selected during experimental evolution enhance replication of a hybrid vaccinia virus with an intermediate transcription factor subunit replaced by the myxoma virus ortholog.
    J Virol. 2018 Jul 25. pii: JVI.01089-18. doi: 10.1128/JVI.01089.
    PubMed     Text format     Abstract available


  77. CHIUPPESI F, Nguyen J, Park S, Contreras H, et al
    Multi-Antigenic Modified Vaccinia Ankara Vaccine Vectors to Elicit Potent Humoral and Cellular Immune Reponses Against Human Cytomegalovirus in Mice.
    J Virol. 2018 Jul 25. pii: JVI.01012-18. doi: 10.1128/JVI.01012.
    PubMed     Text format     Abstract available


  78. BROECKER F, Liu STH, Sun W, Krammer F, et al
    Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.
    J Virol. 2018 Jul 25. pii: JVI.01100-18. doi: 10.1128/JVI.01100.
    PubMed     Text format     Abstract available


  79. MILLER-NOVAK LK, Das J, Musich TA, Demberg T, et al
    Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques.
    J Virol. 2018 Jul 18. pii: JVI.00721-18. doi: 10.1128/JVI.00721.
    PubMed     Text format     Abstract available


  80. CHAN KW, Pan R, Costa M, Gorny MK, et al
    Structural Comparison of Human Anti-HIV-1 gp120 V3 MAbs of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    J Virol. 2018 Jul 11. pii: JVI.00641-18. doi: 10.1128/JVI.00641.
    PubMed     Text format     Abstract available


  81. MEHTA N, Enwere EK, Dos Santos T, Saffran HA, et al
    Expression of the vaccinia virus anti-apoptotic F1 protein is blocked by PKR in the absence of the viral E3 protein.
    J Virol. 2018 Jul 11. pii: JVI.01167-18. doi: 10.1128/JVI.01167.
    PubMed     Text format     Abstract available


  82. HOVANESSIAN AG, Soundaramourty C, Benferhat R, Le Grand R, et al
    Vaccination with the conserved caveolin-1 binding motif in HIV-1 glycoprotein gp41 delays the onset of viral infection and provides partial protection in SHIV-challenged cynomolgus macaques.
    J Virol. 2018 Jul 5. pii: JVI.00370-18. doi: 10.1128/JVI.00370.
    PubMed     Text format     Abstract available


  83. MENACHERY VD, Gralinski LE, Mitchell HD, Dinnon KH 3rd, et al
    Combination attenuation offers strategy for live-attenuated coronavirus vaccines.
    J Virol. 2018 Jul 5. pii: JVI.00710-18. doi: 10.1128/JVI.00710.
    PubMed     Text format     Abstract available


  84. CAO QM, Ni YY, Cao D, Tian D, et al
    Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Membrane-Bound Interleukin-15 as an Immunomodulatory Adjuvant Enhances NK and gammadelta T Cell Responses and Confers Heterologous Protection.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


    June 2018
  85. ZHANG M, Sun Y, Chen W, Bu Z, et al
    The 135 gene of goatpox virus encodes an inhibitor of nuclear factor-kappaB and apoptosis and may serve as an improved insertion site to generate vectored live vaccine.
    J Virol. 2018 Jun 27. pii: JVI.00190-18. doi: 10.1128/JVI.00190.
    PubMed     Text format     Abstract available


  86. VIKTOROVA EG, Khattar SK, Kouiavskaia D, Laassri M, et al
    Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
    J Virol. 2018 Jun 20. pii: JVI.00976-18. doi: 10.1128/JVI.00976.
    PubMed     Text format     Abstract available


  87. LI P, Ke X, Wang T, Tan Z, et al
    Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models.
    J Virol. 2018 Jun 20. pii: JVI.00701-18. doi: 10.1128/JVI.00701.
    PubMed     Text format     Abstract available


  88. WALZ L, Kays SK, Zimmer G, von Messling V, et al
    Sialidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    J Virol. 2018 Jun 20. pii: JVI.01006-18. doi: 10.1128/JVI.01006.
    PubMed     Text format     Abstract available


  89. KHAN AA, Srivastava R, Vahed H, Roy S, et al
    Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107(+) CD8(+) T Cells That Infiltrate the Cornea and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protec
    J Virol. 2018 Jun 13. pii: JVI.00535-18. doi: 10.1128/JVI.00535.
    PubMed     Text format     Abstract available


  90. MARTINS MA, Tully DC, Pedreno-Lopez N, von Bredow B, et al
    Mamu-B*17+ rhesus macaques vaccinated with env, vif, and nef manifest early control of SIVmac239 replication.
    J Virol. 2018 Jun 6. pii: JVI.00690-18. doi: 10.1128/JVI.00690.
    PubMed     Text format     Abstract available


  91. IAMPIETRO MJ, Larocca RA, Provine NM, Abbink P, et al
    Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


    May 2018
  92. SINGH S, Ramirez-Salazar EG, Doueiri R, Valentin A, et al
    Control of Heterologous SIVsmE660 infection by DNA and Protein Co-immunization Regimens Combined with Different Toll-like Receptor-4 (TLR-4) Based Adjuvants in Macaques.
    J Virol. 2018 May 23. pii: JVI.00281-18. doi: 10.1128/JVI.00281.
    PubMed     Text format     Abstract available


  93. SULLIVAN NL, Reuter-Monslow MA, Sei J, Durr E, et al
    Breadth and functionality of varicella zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans.
    J Virol. 2018 May 9. pii: JVI.00269-18. doi: 10.1128/JVI.00269.
    PubMed     Text format     Abstract available


  94. ELSAYED H, Nabi G, McKinstry WJ, Khoo KK, et al
    Intrastructural Help: Harnessing T-Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
    J Virol. 2018 May 9. pii: JVI.00141-18. doi: 10.1128/JVI.00141.
    PubMed     Text format     Abstract available


    April 2018
  95. SANTOS ROCHA C, Hirao LA, Weber MG, Mendez-Lagares G, et al
    Subclinical cytomegalovirus infection associates with altered host immunity, gut microbiota and vaccine responses.
    J Virol. 2018 Apr 18. pii: JVI.00167-18. doi: 10.1128/JVI.00167.
    PubMed     Text format     Abstract available


  96. OZOROWSKI G, Cupo A, Golabek M, LoPiccolo M, et al
    Effects of adjuvants on HIV-1 envelope glycoprotein SOSIP trimers in vitro.
    J Virol. 2018 Apr 18. pii: JVI.00381-18. doi: 10.1128/JVI.00381.
    PubMed     Text format     Abstract available


  97. BRICAULT CA, Kovacs JM, Badamchi-Zadeh A, McKee K, et al
    Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.
    J Virol. 2018 Apr 11. pii: JVI.00369-18. doi: 10.1128/JVI.00369.
    PubMed     Text format     Abstract available


    March 2018
  98. CARNEC X, Mateo M, Page A, Reynard S, et al
    A vaccine platform against arenaviruses based on a recombinant hyper-attenuated Mopeia virus expressing heterologous glycoproteins.
    J Virol. 2018 Mar 28. pii: JVI.02230-17. doi: 10.1128/JVI.02230.
    PubMed     Text format     Abstract available


  99. BARBAN V, Mantel N, De Montfort A, Pagnon A, et al
    Improvement of Dengue Non-Human Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against Dengue 2 and Dengue 4.
    J Virol. 2018 Mar 28. pii: JVI.00440-18. doi: 10.1128/JVI.00440.
    PubMed     Text format     Abstract available


  100. WANG W, Song HS, Keller PW, Alvarado-Facundo E, et al
    Conformational stability of the hemagglutinin of H5N1 influenza A viruses influences susceptibility to broadly neutralizing stem antibodies.
    J Virol. 2018 Mar 28. pii: JVI.00247-18. doi: 10.1128/JVI.00247.
    PubMed     Text format     Abstract available


  101. ALJURAYYAN A, Puksuriwong S, Ahmed M, Sharma R, et al
    Activation and induction of antigen-specific T follicular helper cells (TFH) play a critical role in LAIV-induced human mucosal anti-influenza antibody response.
    J Virol. 2018 Mar 21. pii: JVI.00114-18. doi: 10.1128/JVI.00114.
    PubMed     Text format     Abstract available


  102. AGNIHOTHRAM S, Menachery VD, Yount BL Jr., Lindesmith LC, et al
    Development of a Broadly Accessible VEE Replicon Particle Vaccine Platform.
    J Virol. 2018 Mar 14. pii: JVI.00027-18. doi: 10.1128/JVI.00027.
    PubMed     Text format     Abstract available


  103. BRYK P, Brewer MG, Ward BM
    Vaccinia virus phospholipase protein F13 promotes the rapid entry of extracellular virions into cells.
    J Virol. 2018 Mar 14. pii: JVI.02154-17. doi: 10.1128/JVI.02154.
    PubMed     Text format     Abstract available


  104. LAW JLM, Logan M, Wong J, Kundu J, et al
    Role of the E2 hypervariable region (HVR1) in the immunogenicity of a recombinant HCV vaccine.
    J Virol. 2018 Mar 14. pii: JVI.02141-17. doi: 10.1128/JVI.02141.
    PubMed     Text format     Abstract available


  105. BLASS E, Aid M, Martinot AJ, Larocca RA, et al
    Adenovirus vector vaccination impacts NK cell rheostat function following LCMV infection.
    J Virol. 2018 Mar 7. pii: JVI.02103-17. doi: 10.1128/JVI.02103.
    PubMed     Text format     Abstract available


  106. LAZARO-FRIAS A, Gomez-Medina S, Sanchez-Sampedro L, Ljungberg K, et al
    Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.
    J Virol. 2018 Mar 7. pii: JVI.00363-18. doi: 10.1128/JVI.00363.
    PubMed     Text format     Abstract available


  107. WAN Y, Kang G, Sreenivasan C, Daharsh L, et al
    A DNA vaccine expressing consensus hemagglutinin-esterase fusion protein protected guinea pigs from infection by two lineages of influenza D virus.
    J Virol. 2018 Mar 7. pii: JVI.00110-18. doi: 10.1128/JVI.00110.
    PubMed     Text format     Abstract available


    February 2018
  108. GU J, Hardy J, Boo I, Vietheer P, et al
    Escape of Hepatitis C virus from epitope I neutralization increases sensitivity of other neutralization epitopes.
    J Virol. 2018 Feb 21. pii: JVI.02066-17. doi: 10.1128/JVI.02066.
    PubMed     Text format     Abstract available


  109. POUYANFARD S, Spagnoli G, Bulli L, Balz K, et al
    Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    J Virol. 2018;92.
    PubMed     Text format     Abstract available


  110. LIU R, Moss B
    Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state.
    J Virol. 2018 Feb 14. pii: JVI.00053-18. doi: 10.1128/JVI.00053.
    PubMed     Text format     Abstract available


  111. JEGASKANDA S, Mason RD, Andrews SF, Wheatley AK, et al
    Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes.
    J Virol. 2018 Feb 14. pii: JVI.01970-17. doi: 10.1128/JVI.01970.
    PubMed     Text format     Abstract available


  112. LOPES PP, Todorov G, Pham TT, Nesburn AB, et al
    Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8(+) TEM and TRM Cell Responses Against Herpes Infection and Disease(double dagger).
    J Virol. 2018 Feb 7. pii: JVI.02156-17. doi: 10.1128/JVI.02156.
    PubMed     Text format     Abstract available


  113. SAUNDERS KO, Santra S, Parks R, Yates NL, et al
    Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.
    J Virol. 2018 Feb 7. pii: JVI.02035-17. doi: 10.1128/JVI.02035.
    PubMed     Text format     Abstract available


  114. WIJESUNDARA DK, Gummow J, Li Y, Yu W, et al
    Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice.
    J Virol. 2018 Feb 7. pii: JVI.02133-17. doi: 10.1128/JVI.02133.
    PubMed     Text format     Abstract available


    January 2018
  115. JANKOVICH JK, Chapman D, Hansen DT, Robida MD, et al
    Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins.
    J Virol. 2018 Jan 31. pii: JVI.02219-17. doi: 10.1128/JVI.02219.
    PubMed     Text format     Abstract available


  116. YATES NL, deCamp AC, Korber BT, Liao HX, et al
    HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
    J Virol. 2018 Jan 31. pii: JVI.01843-17. doi: 10.1128/JVI.01843.
    PubMed     Text format     Abstract available


  117. TORRENTS DE LA PENA A, de Taeye SW, Sliepen K, LaBranche CC, et al
    Immunogenicity in rabbits of SOSIP trimers from clades A, B and C, given individually, sequentially or in combinations.
    J Virol. 2018 Jan 24. pii: JVI.01957-17. doi: 10.1128/JVI.01957.
    PubMed     Text format     Abstract available


  118. PERMAR SR, Schleiss MR, Plotkin SA
    Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.
    J Virol. 2018 Jan 17. pii: JVI.00030-18. doi: 10.1128/JVI.00030.
    PubMed     Text format     Abstract available


  119. WILLS S, Hwang KK, Liu P, Dennison SM, et al
    HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis.
    J Virol. 2018 Jan 10. pii: JVI.01552-17. doi: 10.1128/JVI.01552.
    PubMed     Text format     Abstract available


  120. MOSTAFA HH, Thompson TW, Konen AJ, Haenchen SD, et al
    Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.
    J Virol. 2018 Jan 10. pii: JVI.01654-17. doi: 10.1128/JVI.01654.
    PubMed     Text format     Abstract available


  121. ABBINK P, Kirilova M, Boyd M, Mercado N, et al
    Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
    J Virol. 2018 Jan 3. pii: JVI.01924-17. doi: 10.1128/JVI.01924.
    PubMed     Text format     Abstract available


  122. XU K, Song Y, Dai L, Zhang Y, et al
    Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
    J Virol. 2018 Jan 3. pii: JVI.01722-17. doi: 10.1128/JVI.01722.
    PubMed     Text format     Abstract available


    December 2017
  123. ROSTAD CA, Stobart CC, Todd SO, Molina SA, et al
    ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.
    J Virol. 2017 Dec 20. pii: JVI.01568-17. doi: 10.1128/JVI.01568.
    PubMed     Text format     Abstract available


  124. LIANG R, Sun Y, Liu Y, Wang J, et al
    Major histocompatibility complex class I (FLA-E*01801) molecular structure in domestic cats demonstrates species-specific characteristics in presenting viral antigen peptides.
    J Virol. 2017 Dec 20. pii: JVI.01631-17. doi: 10.1128/JVI.01631.
    PubMed     Text format     Abstract available


  125. LI C, Zhou H, Zhang H, Wang S, et al
    Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.
    J Virol. 2017;91.
    PubMed     Text format    


  126. KASANI SK, Cheng HY, Yeh KE, Chang SJ, et al
    Reply to "Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein".
    J Virol. 2017;91.
    PubMed     Text format    


  127. REIS AL, Goatley LC, Jabbar T, Sanchez-Cordon PJ, et al
    Deletion of the African Swine Fever Virus Gene DP148R Does Not Reduce Virus Replication in Culture but Reduces Virus Virulence in Pigs and Induces High Levels of Protection against Challenge.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  128. JONES AT, Chamcha V, Kesavardhana S, Shen X, et al
    A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.
    J Virol. 2017 Dec 13. pii: JVI.01796-17. doi: 10.1128/JVI.01796.
    PubMed     Text format     Abstract available


  129. CHEN C, Liu L, Xiao Y, Cui S, et al
    Structural insight into a human neutralizing antibody against influenza virus H7N9.
    J Virol. 2017 Dec 6. pii: JVI.01850-17. doi: 10.1128/JVI.01850.
    PubMed     Text format     Abstract available


  130. ROYER DJ, Carr DJJ
    Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"
    J Virol. 2017;91.
    PubMed     Text format    


  131. GHIASI H
    Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    J Virol. 2017;91.
    PubMed     Text format    


    November 2017
  132. ERASMUS JH, Seymour RL, Kaelber JT, Kim DY, et al
    Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono- and multi-valent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Nov 29. pii: JVI.01274-17. doi: 10.1128/JVI.01274.
    PubMed     Text format     Abstract available


  133. MATASSOV D, Mire CE, Latham T, Geisbert JB, et al
    Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190.
    PubMed     Text format     Abstract available


  134. JERE KC, Chaguza C, Bar-Zeev N, Lowe J, et al
    Emergence of double- and triple-gene reassortant G1P[8] rotaviruses possessing a DS-1-like backbone post rotavirus vaccine introduction in Malawi.
    J Virol. 2017 Nov 15. pii: JVI.01246-17. doi: 10.1128/JVI.01246.
    PubMed     Text format     Abstract available


  135. MALHERBE DC, Mendy J, Vang L, Barnette PT, et al
    Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C SHIV Mucosal Challenge.
    J Virol. 2017 Nov 1. pii: JVI.01092-17. doi: 10.1128/JVI.01092.
    PubMed     Text format     Abstract available


  136. GRESETH MD, Czarnecki MW, Bluma MS, Traktman P, et al
    Isolation and Characterization of vDeltaI3 Confirms that the Vaccinia Virus SSB Plays an Essential Role in Viral Replication.
    J Virol. 2017 Nov 1. pii: JVI.01719-17. doi: 10.1128/JVI.01719.
    PubMed     Text format     Abstract available


  137. VAN ERP EA, van Kasteren PB, Guichelaar T, Ahout IML, et al
    In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  138. MONTEAGUDO PL, Lacasta A, Lopez E, Bosch L, et al
    BA71DeltaCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilities.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  139. WARING BM, Sjaastad LE, Fiege JK, Fay EJ, et al
    microRNA-based attenuation of influenza virus across susceptible hosts.
    J Virol. 2017 Nov 1. pii: JVI.01741-17. doi: 10.1128/JVI.01741.
    PubMed     Text format     Abstract available


    October 2017
  140. WANG X, Ku Z, Zhang X, Ye X, et al
    Structure, Immunogenicity and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
    J Virol. 2017 Oct 25. pii: JVI.01330-17. doi: 10.1128/JVI.01330.
    PubMed     Text format     Abstract available


  141. BOGDANOFF WA, Perez EI, Lopez T, Arias CF, et al
    Structural basis for the escape of human astrovirus from antibody neutralization: broad implications for rational vaccine design.
    J Virol. 2017 Oct 25. pii: JVI.01546-17. doi: 10.1128/JVI.01546.
    PubMed     Text format     Abstract available


  142. YORK J, Nunberg JH
    Epistastic interactions within the Junin virus envelope glycoprotein complex provide an evolutionary barrier to reversion in the live-attenuated Candid#1 vaccine.
    J Virol. 2017 Oct 25. pii: JVI.01682-17. doi: 10.1128/JVI.01682.
    PubMed     Text format     Abstract available


  143. SCHONE D, Hrycak CP, Windmann S, Lapuente D, et al
    Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  144. MURA M, Combredet C, Najburg V, Sanchez David RY, et al
    Nonencapsidated 5' Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


  145. MCGUIRE EP, Fong Y, Toote C, Cunningham CK, et al
    HIV exposed infants vaccinated with a MF59/rgp120 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01070-17. doi: 10.1128/JVI.01070.
    PubMed     Text format     Abstract available


  146. SHEN X, Basu R, Sawant S, Beaumont D, et al
    HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01077-17. doi: 10.1128/JVI.01077.
    PubMed     Text format     Abstract available


  147. WONG TM, Allen JD, Bebin-Blackwell AG, Carter DM, et al
    COBRA HA elicits hemagglutination-inhibition antibodies against a panel of H3N2 influenza virus co-circulating variants.
    J Virol. 2017 Oct 4. pii: JVI.01581-17. doi: 10.1128/JVI.01581.
    PubMed     Text format     Abstract available


  148. CARTER DM, Darby CA, Johnson SK, Carlock MA, et al
    Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets pre-immune to historical H1N1 influenza viruses.
    J Virol. 2017 Oct 4. pii: JVI.01283-17. doi: 10.1128/JVI.01283.
    PubMed     Text format     Abstract available


  149. GOFF PH, Hayashi T, He W, Yao S, et al
    Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    September 2017
  150. URAKAMI A, Ngwe Tun MM, Moi ML, Sakurai A, et al
    Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design.
    J Virol. 2017 Sep 27. pii: JVI.01181-17. doi: 10.1128/JVI.01181.
    PubMed     Text format     Abstract available


  151. BAGRI P, Anipindi VC, Nguyen PV, Vitali D, et al
    A novel role for IL-17 in enhancing type 1 helper T cell immunity in the female genital tract following mucosal HSV-2 vaccination.
    J Virol. 2017 Sep 27. pii: JVI.01234-17. doi: 10.1128/JVI.01234.
    PubMed     Text format     Abstract available


  152. MOONEY AJ, Gabbard JD, Li Z, Dlugolenski DA, et al
    Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    J Virol. 2017 Sep 20. pii: JVI.01579-17. doi: 10.1128/JVI.01579.
    PubMed     Text format     Abstract available


  153. ANDERSEN TK, Zhou F, Cox R, Bogen B, et al
    A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza.
    J Virol. 2017 Sep 20. pii: JVI.01340-17. doi: 10.1128/JVI.01340.
    PubMed     Text format     Abstract available


  154. RYERSON MR, Richards MM, Kvansakul M, Hawkins CJ, et al
    Vaccinia virus encodes a novel inhibitor of apoptosis that associates with the apoptosome.
    J Virol. 2017 Sep 13. pii: JVI.01385-17. doi: 10.1128/JVI.01385.
    PubMed     Text format     Abstract available


  155. SAUERMANN U, Radaelli A, Stolte-Leeb N, Raue K, et al
    Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses.
    J Virol. 2017 Sep 13. pii: JVI.01120-17. doi: 10.1128/JVI.01120.
    PubMed     Text format     Abstract available


  156. SULLIVAN JT, Sulli C, Nilo A, Yasmeen A, et al
    High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.
    J Virol. 2017 Sep 6. pii: JVI.00862-17. doi: 10.1128/JVI.00862.
    PubMed     Text format     Abstract available


    August 2017
  157. BROOKE CB
    Population diversity and collective interactions during influenza virus replication and evolution.
    J Virol. 2017 Aug 30. pii: JVI.01164-17. doi: 10.1128/JVI.01164.
    PubMed     Text format     Abstract available


  158. LIU X, Liang B, Ngwuta J, Liu X, et al
    Attenuated human parainfluenza virus type 1 (HPIV1) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from an added gene: effects of pre-fusion stabilization and packaging of RSV F.
    J Virol. 2017 Aug 23. pii: JVI.01101-17. doi: 10.1128/JVI.01101.
    PubMed     Text format     Abstract available


    July 2017
  159. PHAN SI, Zengel JR, Wei H, Li Z, et al
    Parainfluenza virus 5 (PIV5) expressing wild-type or pre-fusion respiratory syncytial virus (RSV) fusion protein protect mice and cotton rats from RSV challenge.
    J Virol. 2017 Jul 26. pii: JVI.00560-17. doi: 10.1128/JVI.00560.
    PubMed     Text format     Abstract available


    May 2017
  160. SHEN X, Bogers WM, Yates NL, Ferrari G, et al
    Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    J Virol. 2017 May 10. pii: JVI.00401-17. doi: 10.1128/JVI.00401.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: